Navigation Links
New treatment holds promise for resistant lung cancer
Date:4/9/2013

WASHINGTON, DC (April 9, 2013)A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors, according findings to be presented by Fox Chase Cancer Center researchers at the AACR Annual Meeting 2013 on Tuesday, April 9.

"I'm very optimistic that we will show this protocol helps lung cancer patients who have run out of other options," says study author Hossein Borghaei, MS, DO, director of Thoracic Medical Oncology at Fox Chase. "For this patient population, we are in desperate need of new treatments."

All of the patients included in the study had non-small cell lung cancer, the most common form of lung cancer. In the U.S., more patients die of lung cancer than any other cancer. All had tried at least one other treatment, but their tumors had continued to grow.

Once patients fail to respond to one therapy, additional treatments are less likely to work, says Borghaei. For patients with treatment-resistant lung cancer, there is often little hope. But in the labs of Fox Chase, researchers have found evidence that a new combination of existing chemotherapy drugs could have an effect on these types of tumors.

The first drug, Tarceva (erlotinib), blocks a pathway many tumors use to grow. The drug works particularly well in lung tumors that carry a mutation which accelerates that particular pathway. None of the patients included in the study carried this mutation, but research suggests they may still see some benefit from Tarceva.

The other drug, Alisertib (MLN8237), prevents chromosomes from splitting normally during cell division, causing cells to die. Since tumors depend on cell division to grow, the drug is being investigated in a number of different types of cancer.

If the drugs work better together than apart in lung tumors, that would make sense, says Borghaei. "What we've found through many years of research is that it's often better to combine chemotherapy drugs that target different aspects of cancer than to use either alone."

To test this theory, Borghaei and his colleagues gave four different doses of the drugs to 10 patientsthe first stage of clinical testing that determines the maximum dose that people can safely tolerate.

Encouragingly, the side effects were "manageable," says Borghaei. One person experienced hair loss and lower counts of blood cells that fight infection, but has not developed any infections, he says. Other patients reported some mild fatigue, "but nothing out of the ordinary that would make us say this is an intolerable regimen," he says.

Although the research is not far enough along to know if the treatment works, 2 patients' tumors stopped growing while taking the drugs. Three patients have unfortunately died, but only after they'd stopped the treatment because their tumors didn't respond.

Borghaei cautions that in such early stages of the research, it's too soon to tell if the treatment works. "Both patients whose tumors stabilized were given the maximum dose of both drugs, and I hope that once we progress in the trial and treat more patients at the maximum doses, we will see more responses," he says. "I want everyone to respond."


'/>"/>

Contact: Diana Quattrone
diana.quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Siberian Pine Nut Oil Provides Tips for Treatment of Gastritis
2. A New Peer-Reviewed Study Using CogniFit Brain Training Provides A Breakthrough In The Treatment Of Insomnia
3. Top Provider of Hearing Aids in Marina del Rey CA, American Hearing & Balance, Now Offers New Balance Disorder Treatment
4. Diabetes patients need to be consulted to improve treatment
5. Extracellular vesicles may open new opportunities for brain cancer diagnosis and treatment
6. Rejuv Medical Announces Stem Cell Treatments Now Available
7. Different drug combinations work best for prevention versus treatment of colorectal tumors
8. Fatty Liver Treatment
9. How “Fatty Liver Diet Guide” Helps People Treat Fatty Liver Quickly – Vkool.com
10. Flies model a potential sweet treatment for Parkinsons disease
11. New minimally invasive, MRI-guided laser treatment for brain tumor found to be promising in study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology: